BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2017
Standard of Care Technology to be Featured in Satellite Symposium, Live Cases, and Podium Presentations
SAN CARLOS, Calif. -- BioTrace Medical, Inc., today announced the company’s key activities at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 meeting, which will take place October 29 - November 2 at the Colorado Convention Center in Denver.
The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled: “The Tempo Temporary Pacing Lead: A New Standard of Care in TAVR”, which will be co-chaired by Susheel K. Kodali, M.D., director of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Medical Center, and Steven Yakubov, M.D., system chief, Advanced Structural Heart Disease, Riverside Methodist Hospital/OhioHealth. (Symposium registration: http://www.crf.org/tct/agenda/satellite-programs?programid=1183.)
The symposium will feature recent clinical experience and case studies from several leading U.S. transcatheter valve aortic replacement (TAVR) centers, highlighting the safety and efficacy of the Tempo Lead, and its positive impact on facilitating post-TAVR patient ambulation and reducing length of stay. These results were observed in more than 500 cases with no perforations, pericardial effusions, or sustained device-related arrhythmias reported.
“Temporary pacing following a TAVR procedure is a key element to the recovery process and as the number of TAVR cases increase, so does the need for a temporary pacing technology that mitigates the risks of perforation and lead dislodgement, and that can facilitate ambulation in the recovery process,” said Stanley Chetcuti, M.D., professor of cardiovascular medicine and director of the cardiac catheterization laboratory at the University of Michigan Health System, and a member of the BioTrace symposium faculty at TCT. “Real-world use of the Tempo Lead continues to demonstrate its ability to provide secure and stable pacing both during and after TAVR procedures and, at the University of Michigan we have been impressed with the unparalleled safety and stability of the Tempo Lead.”